November 29, 2018 / 12:09 PM / in 19 days

Alkermes schizophrenia treatment meets main goals in late-stage study

Nov 29 (Reuters) - Alkermes Plc said on Thursday its treatment for schizophrenia met the main goals in a late-stage study and demonstrated a favorable weight profile, compared with antipsychotic agent olanzapine.

The company said it plans to submit the marketing application to the U.S. Food and Drug Administration in mid-2019. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Anil D’Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below